OncoMatch/Clinical Trials/NCT05483491
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Is NCT05483491 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including KK-LC-1 TCR-T cells and Aldesleukin for gastric cancer.
Treatment: KK-LC-1 TCR-T cells · Aldesleukin — This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Breast Carcinoma
Cervical Cancer
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Biomarker criteria
Required: CT83 expression (≥ 10% of tumor cells positive by ihc)
Required: HLA-A a*01:01
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: cancer type-specific standard of care systemic cancer therapy
Lab requirements
Blood counts
leukocytes > 3,000/mcl; absolute neutrophil count > 1,500/mcl; platelets > 100,000/mcl; hemoglobin > 9.0 g/dl; inr or aptt ≤ 1.5 x uln unless the subject is receiving anticoagulant therapy. subjects on anticoagulant therapy must have a pt or ptt within therapeutic range and no history of severe hemorrhage.
Kidney function
calculated creatinine clearance (crcl) > 50 ml/min/1.73 m² for participants with creatinine levels above institutional normal.
Liver function
total bilirubin within normal institutional limits except in participants with gilbert's syndrome who must have a total bilirubin < 3.0 mg/dl. serum ast (sgot)/alt (sgpt) < 2.5 x uln.
Cardiac function
lvef > 45% required; exclusion for history of coronary revascularization or ischemic symptoms unless normal cardiac stress test; exclusion for clinically significant arrhythmias.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rutgers Cancer Institute · New Brunswick, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital · New Brunswick, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05483491 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received cancer type-specific standard of care systemic cancer therapy.
Does this trial require CT83?
Yes, CT83 expression is a required biomarker for enrollment.
Does this trial require HLA-A?
Yes, HLA-A a*01:01 is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages